Making a difference: Molecules, mechanisms and more

Editor’s Choice: A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancerEditor’s Choice: Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancerEditorial: From one-size-fits all to biology-driven care: Emerging paradigms in gynecologic oncologyHosted by:Paola Gehrig, MD, Associate Editor of Gynecologic OncologyFeaturing:Bradley Corr, University of Colorado, Aurora, CO, USAUrsula Matulonis, Dana-Farber Cancer Institute, Boston, MA, USAMary M. Mullen, Washington University School of Medicine, St Louis, MO, USARebecca Arhend, University of Alabama at Birmingham, Birmingham, AL, USACheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net